Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of
patients with Cushing's disease. It was a pivotal trial which supported the registration of
LCI699 for the treatment of patients with Cushing's disease in the US and the EU.
This is a phase lll, multi-center, double-blind, randomized withdrawal study of LCI699
following a 24 week, single-arm, open-label dose titration and treatment period which
evaluated the safety and efficacy of LCI699 for the treatment of patients with Cushing's
disease.